Using our proprietary Enhanced Design and Combine (EDC) chemistry platform, we are developing an emerging portfolio of novel designer immunotherapies for the treatment of cancer and autoimmune diseases.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2017
  • Number of employees in Switzerland
    20-49
Key business

You may also be interested in